Introduction {#sec1-1}
============

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory bone disease occurring primarily in children and adolescents. Auto-inflammatory diseases are disorders of innate immunity characterized by absence of autoantibodies in high titres and autoreactive lymphocytes. CRMO is also known more recently as chronic nonbacterial osteomyelitis and was first described in 1972 by Giedion *et al*.[@ref1]

The clinical presentation of CRMO can vary from asymptomatic or mild inflammation of single site (metaphysis of the bone) which tends to be time limited to CRMO. Patients present with insidious onset of pain, swelling, localised skin redness and tenderness of the involved bones. It is typically seen in the metaphysis of long bones, clavicle, and vertebral bodies.[@ref2] Rarely other sites, including mandible, pelvis and small bones of the hands and feet can be involved. A subset of patients with CRMO may present with psoriasis, inflammatory bowel disease and acne. There is no widely accepted diagnostic criterion and hence, CRMO remains a diagnosis of exclusion. Blood investigations reveal nonspecific evidence of inflammation. Whole body magnetic resonance imaging (MRI) is the imaging of choice for diagnosis of CRMO. CRMO is a diagnosis of exclusion with a caveat that infection and malignancy (especially Langerhan\'s cell histiocytosis) be ruled out.[@ref3]

CRMO can have a monogenic inheritance or can be sporadic. Majeed syndrome is an autosomal recessive condition caused by mutation of LPIN2 gene associated with CRMO, neutrophilic dermatosis and dyserythropoietic anemia. It has been described predominantly in patients from West Asia. The authors have described 2 patients from the same family who were genetically proven to be Majeed syndrome, first time to be ever described from the Indian subcontinent.[@ref4]

CRMO is considered the pediatric equivalent of synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome. SAPHO syndrome is characterized by a combination of osteoarticular and dermatological manifestations.[@ref5]

The objective of our study was to understand the clinical presentation and short-term outcome of treatment of CRMO patients. This study reiterates the fact that this condition is not so uncommon and has a significant delay in diagnosis as a result of ignorance amongst the orthopedic surgeons and pediatricians.

Materials and Methods {#sec1-2}
=====================

6 patients were diagnosed and treated as CRMO between 2011 and 2016, at our institute. Case records were retrospectively reviewed for clinical features, investigations and treatment of these children. The diagnosis of CRMO was based on the history of insidious onset of bone pain and/or swelling and presence of radiologic evidence of multiple osteolytic lesions in the long bones/bone biopsies showing sterile chronic inflammation. Informed written consent from all the patients was obtained. Ethics approval was not required in accordance with the policy of the institution and verbal informed consent from all the patients/parents was obtained.

Results {#sec1-3}
=======

Over a 4 year period, 6 patients were diagnosed as CRMO and all were boys \[[Table 1](#T1){ref-type="table"}\]. The median age of onset of symptoms was 8 years (range 2--10 years) and the median age of diagnosis was 13 years (range 10--16 years). The median time from onset of symptoms to diagnosis was 3.5 years (range 2--13 years). Pain with or without swelling was the most common symptom. Two out of 6 patients presented with low grade fever. Tibia and fibula were involved in all the patients. Femur, tarsals and metatarsals were involved in 4 out of 6 patients (66.7%). Mandibular, clavicular, pelvic, rib and vertebral body involvement were seen in one out of 6 (not in the same patient). One patient with anemia with leucopenia and was subjected to a bone marrow examination, which revealed congenital dyserythropoietic anemia (later diagnosed as Majeed syndrome). Erythrocyte sedimentation rate (ESR) was elevated in all patients except one, with a median ESR of 61.5 mm/h (range 8--70 mm/h).

###### 

The clinical details and blood investigations at the time of diagnosis
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Two children underwent bone biopsy, which showed chronic inflammatory changes with presence of sclerotic bone. The cultures of the bone biopsy were sterile in both these patients. All patients except one underwent MRI of the affected region. This patient being the cousin of the proband with Majeed syndrome had clinical features and radioisotope bone scan which were suggestive of CRMO and his genetic analysis revealed that he shared the same LPIN2 mutation. MRI was done in 5 out of 6 patients and was suggestive of CRMO in all the five patients \[[Figure 1](#F1){ref-type="fig"}\]. Two patients underwent genetic studies and were found to have LPIN2 mutation \[[Table 2](#T2){ref-type="table"}\]. Both these patients were cousins who were diagnosed to have Majeed syndrome.

![MRI T2W sagittal image showing multiple osteolytic lesions in tibia, calcaneum and talus](IJOrtho-52-672-g002){#F1}

###### 

The imaging, biopsy, genetic studies and treatment of all six patients
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All patients were initially treated with on nonsteroidal anti-inflammatory drugs (NSAIDs) and methotrexate. Three out of 6 patients responded to this combination treatment. The remaining three patients were given the option of either bisphosphonates (pamidronate) or tumour necrosis factor α (TNF α) blockers. Two patients out of the three, who were given this choice preferred pamidronate infusion, given for 3 days every 3 monthly once at 0.5 mg/kg on day 1 and 1 mg/kg on day 2 and 3 \[[Table 2](#T2){ref-type="table"}\], because of lower cost of treatment and less frequent administration. The index case diagnosed to have Majeed syndrome responded partially to a combination of 3 monthly pamidronate with methotrexate and required intermittent NSAIDs for control of symptoms with frequent flares. TNF α blocker (etanercept biosimilar) was used intermittently (due to financial constraints) to control the flare on a weekly basis on 2 occasions a year apart. The second patient did well on 3 monthly pamidronate. The third patient was started on weekly etanercept (TNF α blocker) and has done very well with significant reduction in the intensity and frequency of symptoms.

The median duration of followup was 31.5 months.

Discussion {#sec1-4}
==========

CRMO is a rare autoinflammatory bone disorder, commonly found in the long bones of children. This is the first case series from the Indian subcontinent. The mean age of onset reported in literature is 10 years (range 4--17 years) which is very similar to our study. There was a significant delay in diagnosis (median duration of time from onset to diagnosis-3.5 years) which is mostly related to the fact that there is lack of awareness about this condition amongst the care providers in this part of the world. All the affected patients in our series were male in contrast to other studies which have reported female preponderance.[@ref6] This could just have been a result of referral bias.

The pathophysiology of CRMO remains unknown. Recent studies have found an imbalance between pro-(interleukin-6 \[IL-6\], TNF-α) and anti-inflammatory (IL-10) cytokines may be centrally involved in the molecular pathology of CRMO.[@ref7]

The most common symptom is insidious onset bone pain.[@ref8] The pain usually is dull aching, which can be interspersed with a shooting pain in a few patients. Swelling, warmth and tenderness of the affected bone can also be present. Intermittent episodes of exacerbation and remission can be seen in many of these patients. Other organs like the eyes, skin, gastrointestinal system and lungs can also be involved.

Only one patient (Index case of Majeed syndrome) had presence of extra osseous manifestation in the form of congenital dyserythropoietic anemia. Rest of the patients had isolated bone disease. Remission of the disease can be natural or therapeutically induced.

The lower limb bones were the most commonly involved which was similar to other studies.[@ref9][@ref10] Clavicle was not a commonly involved site in the patients in our series unlike other case series.

Laboratory investigations like total leucocyte count, ESR and C-reactive protein may be normal or reveal only minor alterations.[@ref11] Almost all our patients except one had an elevated ESR (83.3%) and this is slightly different from other similar studies.[@ref3]

Plain radiographs reveal osteolytic lesions surrounded by sclerosis. MRI is the imaging modality of choice. MRI was confirmatory in 5 out of 6 patients. Whole body MRI was done in only one patient because of cost constraints. Bone biopsy is done to rule out infection or neoplasm.[@ref12] Two of our patients underwent bone biopsy, which revealed chronic inflammatory cells with sclerotic bone. A diagnostic criteria for CRMO was framed by Roderick *et al* \[[Table 3](#T3){ref-type="table"}\].

###### 

Bristol diagnostic criteria for chronic recurrent multifocal osteomyelitis
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There is a significant genetic contribution to CRMO disease susceptibility. Two monogenic syndromic forms of CRMO include deficiency of IL-1 receptor antagonist (DIRA) due to mutations in IL1RN and Majeed syndrome due to mutations in LPIN2.[@ref10] Recently there is some evidence that sporadic or nonsyndromic CRMO might have a genetic basis. Majeed Syndrome presents with CRMO, dyserythropoietic anemia and neutrophilic dermatosis. Two of the patients in our series were diagnosed as Majeed syndrome with LPIN2 mutation in our study.[@ref4] DIRA is an autoinflammatory disorder that presents in the neonatal period with generalized pustulosis, osteitis, periostitis, and systemic inflammation due to mutations in IL1RN.[@ref11][@ref13] It is a life threatening disorder that presents in the neonatal period and has an autosomal recessive inheritance.

The optimal treatment strategy of CRMO is still not known.[@ref14] NSAIDs are the first line of treatment for CRMO.[@ref15][@ref16] In this series, methotrexate was added at the time of diagnosis in view of literature showing that it may be helpful when the response to NSAIDs has been suboptimal.[@ref17][@ref18][@ref19] It may also help to reduce the prolonged NSAID use in many of these patients. Barral Mena *et al*. reported that 6 of the 7 patients with CRMO did not respond to naproxen and required other drugs to control the disease better.[@ref20]

Recently bisphosphonates (pamidronate) and biological agents like TNF α blockers have been increasingly used in patients who fail standard therapy.[@ref21][@ref22] The treatment is mostly affordable and long term followup is required as in any chronic disease.

The repeat imaging MRI in the patients treated with etanercept hasn't been done as yet as the duration of treatment has been short and due to financial implications. There are various other studies on CRMO worldwide \[[Table 4](#T4){ref-type="table"}\] and ours is the first case series from India.

###### 

Other studies on chronic recurrent multifocal osteomyelitis
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The limitations of the study were a small sample size, short duration of followup and lack of information of other occult bone involvement since whole body MRI was not done in all patients.

Clinical relevance {#sec2-1}
------------------

There is significant delay in diagnosis of CRMO and this could be because of a lack of awareness of this condition amongst the physicians (orthopedic surgeons and pediatricians). This study was to create the awareness and highlight the fact that CRMO does exist in the community and is amenable to treatment.
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